TP53 and non-small cell lung carcinoma: In a study conducted on non-small cell lung cancer (NSCLC) patients, the authors disclosed that loss of heterozygosity (LOH) for hDMP1 is connected with better prognosis, whereas that of TP53, with impaired prognosis [91].